Poor
Misaligned
Patient Risk:
Moderate
Summary
Partial alignment with the label’s broad indication and age coverage, but multiple key usage/eligibility statements about “responsiveness” determination and “sapropterin-responsive phenotype” are not supported by the provided label excerpts and are treated as non-adherent.
Category Scores
Accurate Statements
Sapropterin is used to treat certain forms of hyperphenylalaninemia and phenylketonuria (PKU).
Label supports indication for reducing blood Phe levels in adult and pediatric patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive PKU (Section 1 INDICATIONS AND USAGE).
Unsupported Statements
Responsiveness for sapropterin in PKU is often determined by a responsiveness test.
No explicit labeling support provided for how responsiveness is “often determined” (Sections 1 and 14 excerpts do not state a general, practice-level “responsiveness test” method).
Mild hyperphenylalaninemia is also typically described as having a sapropterin-responsive phenotype.
Provided label excerpt does not describe mild HPA as “sapropterin-responsive phenotype.”
Sapropterin studies typically include adults with PKU/mild hyperphenylalanemia who meet responsiveness criteria.
While Study 2 describes placebo-controlled adults who responded in Study 1, the claim is framed broadly about “mild hyperphenylalanemia” and “responsiveness criteria” and is not explicitly supported by the provided label excerpts.
Eligibility for sapropterin in practice depends on whether a patient’s phenotype is likely to respond, rather than age alone.
The provided label excerpt specifies age range (≥1 month) and BH4-responsive PKU/HPA indication, but does not state that eligibility depends on phenotype likelihood rather than age.
Responsiveness for sapropterin is often assessed with a pre-treatment test or inferred from clinical context or genotype.
No explicit labeling support provided for these specific responsiveness assessment approaches.
Contradictions
Important Omissions
Label indication requires use in conjunction with a Phe-restricted diet; this diet requirement is not stated in the evaluated claims.
Importance:
Moderate
Label specifies indication for adult and pediatric patients one month of age and older with HPA due to BH4-responsive PKU; the evaluated claims do not explicitly include the BH4-responsive qualifier.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported statements about how “responsiveness” is determined and broad eligibility/phenotype framing may lead to inappropriate patient selection or misunderstanding of labeled criteria; omission of diet conjunction and BH4-responsive qualifier also reduces label fidelity.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Misaligned
Primary Issue
Multiple key practice-relevant statements about responsiveness determination and phenotype framing are not supported by the provided label excerpts.
Suggested Improvement
Limit claims to the label’s explicit indication language (HPA due to BH4-responsive PKU; use with a Phe-restricted diet; adult/pediatric ≥1 month) and avoid stating general clinical testing/inference methods for responsiveness or describing mild HPA as having a “sapropterin-responsive phenotype” unless supported by the provided prescribing information.